Navigation Links
3-Drug Combo Improves Advanced Pancreatic Cancer Outcomes
Date:6/2/2008

Study finds treatment well-tolerated, kept tumors stable for almost 6 months

MONDAY, June 2 (HealthDay News) -- A combination therapy of gemcitabine, capecitabine and bevacizumab improves outcomes in patients with advanced pancreatic cancer, according to a multi-center study led by researchers at Roswell Park Cancer Institute in Buffalo, N.Y.

The study of 50 patients found that this combination treatment was well-tolerated by patients, was able to prevent tumors from progressing for almost six months, and improved median survival to 9.8 months.

The study was expected to be presented Monday at the American Society of Clinical Oncology annual meeting, in Chicago.

Patients with advanced pancreatic cancer -- one of the most deadly types of solid tumors -- have a median survival of six months after diagnosis. About 37,680 people in the United States will be diagnosed with pancreatic cancer in 2008.

While gemcitabine and capecitabine have improved quality of life for patients with advanced pancreatic cancer, they haven't led to a significant improvement in survival time, according to background information in the study.

Bevacizumab, which reduces blood supply to tumor, has improved outcomes when added to chemotherapy for patients with colon, lung and breast cancers.

More information

The National Cancer Institute has more about pancreatic cancer.



-- Robert Preidt



SOURCE: Roswell Park Cancer Institute, news release, June 2, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. 3-drug combination extremely promising as first-line therapy for multiple myeloma
2. Radiation and drug combo helps boost efficacy of lung cancer treatment
3. Aerobic, Weight Training Combo Best Against Diabetes
4. New antibiotic drug combo to speed up treatment of tuberculosis
5. Drug Combo Helps Fight Marfan Syndrome
6. Drug Combo Blocks Pain Without Impairing Movement
7. Two-Drug Combo Fights Brain Tumors
8. CPR, Defibrillator Combo Boosts Cardiac Incident Survival
9. Drug Combo Boosts Multiple Myeloma Survival
10. Drug Combos Effective Against Rheumatoid Arthritis
11. Combo PET/CT Scan Helps Spot Breast Cancers Spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
Breaking Medicine Technology: